
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Beam is seeking a highly talented and motivated VP of Pharmaceutical Sciences, to support our advancing portfolio of in-vivo and ex-vivo programs. Serving as a subject matter expert, this leader will be accountable for supporting all our cell-based potency assays. Their role will also drive our drug product development of our targeting moieties for our LNP platform and other macromolecules. They will support the lifecycle of the targeted drug product from IND submission through BLA approval. The candidate will define the strategic direction for our potency assays and key analytical methods, partnering closely with key stakeholders across the Pharmaceutical Sciences team. This is a high-impact leadership role requiring a data-driven, collaborative, results-oriented professional to ensure rapid progression of our key drug products through clinical development into commercial. This person will be responsible for comprehensive communication across all levels of the business, status reporting, risk management, escalation and resolution of issues.
Primary Responsibilities:
Qualifications:
The salary range below reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on several factors including, but not limited to, relevant experience, education, scope of job, internal comparisons, and market data.

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes.
Our dream is to provide life-long cures for patients suffering from serious diseases.
The Beam Team Is:
• A community of fearless innovators
• Rigorous and honest in our research
• Listening with open minds
• Committed to each other